4//SEC Filing
PAKIANATHAN DEEPIKA 4
Accession 0000950170-24-070991
CIK 0001503802other
Filed
Jun 6, 8:00 PM ET
Accepted
Jun 7, 7:18 PM ET
Size
15.1 KB
Accession
0000950170-24-070991
Insider Transaction Report
Form 4
PAKIANATHAN DEEPIKA
Director
Transactions
- Sale
Common Stock
2024-06-05$0.96/sh−463,518$444,143→ 346,615 total(indirect: See footnote) - Sale
Common Stock
2024-06-06$0.98/sh−1,145$1,125→ 2,240 total(indirect: See footnote) - Sale
Common Stock
2024-06-07$0.95/sh−229,308$218,003→ 0 total(indirect: See footnote) - Sale
Common Stock
2024-06-05$0.96/sh−4,526$4,337→ 3,385 total(indirect: See footnote) - Sale
Common Stock
2024-06-06$0.98/sh−117,307$115,289→ 229,308 total(indirect: See footnote) - Sale
Common Stock
2024-06-07$0.95/sh−2,240$2,130→ 0 total(indirect: See footnote)
Footnotes (5)
- [F1]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.899 to $0.989, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.97 to $1.0302, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9303 to $0.965, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.
- [F5]The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.
Documents
Issuer
Karyopharm Therapeutics Inc.
CIK 0001503802
Entity typeother
Related Parties
1- filerCIK 0001270734
Filing Metadata
- Form type
- 4
- Filed
- Jun 6, 8:00 PM ET
- Accepted
- Jun 7, 7:18 PM ET
- Size
- 15.1 KB